ArticleJournal of neuro-oncology2025
Treatment differences in IDH-wildtype glioma - the impact of surgery and adjuvant therapy.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lower-grade glioma imaging volumes and survival: a single-institution analysis of 90 patients after resection using intraoperative MRI.Journal of neuro-oncology · 2026Article
- Two-decade clinicopathological spectrum of gliomas at a tertiary center in LMIC: histological profile and the molecular diagnostic gap.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesIsocitrate dehydrogenase (IDH) wildtype (wt) astrocytomas without the microscopic features of glioblastoma have high recurrence rates and were re-classified in the presence of certain molecular features as CNS WHO grade 4 tumors in the latest WHO classification of 2021. This study examines the clinical heterogeneity within this histologically defined group and explores implications for treatment decisions, with particular focus on the role of surgical resection.
methodsData acquisition was conducted as a multi-center retrospective analysis at 6 University Hospitals (2016-2019). Patients with IDH-wt diffuse astrocytoma without histological features of glioblastoma were enrolled. Patients presenting with IDH-wt classical glioblastoma from one institution served as controls. Primary outcome parameters were extent of resection (EOR) according to RANO 2.0 criteria, progression-free survival (PFS), and overall survival (OS).
results160 patients with IDH-wt astrocytoma (37.5 % females) and 203 patients with IDH-wt glioblastoma (43.8 % females), were enrolled. The median age in patients with astrocytoma was younger (58.1 vs. 67.6 years; p<0.0001). Mean overall survival was significantly longer in astrocytomas (36.1 ±15.1 months) compared to glioblastomas (17.9 ±2.7 months) (p<0.0001). The extent of tumor resection is a significant factor for PFS and OS in both groups. In IDH-wt astrocytoma OS is doubled after resection of more than 50% of radiographic tumor and tripled if resection of >98% is achieved. In IDH-wt glioblastoma, resection of more than 80% of the tumor volume is needed to achieve tripled OS. MGMT methylation was not associated with longer survival in IDH-wt astrocytoma (p=.2124). While concomitant radiochemotherapy (Stupp/CeTeG) was superior to monotherapy in IDH-wt glioblastoma (p=.0094) it is non-superior to sequential therapy (radiotherapy followed by chemotherapy) in IDH-wt astrocytoma (p=.1134).
conclusionThe presented data suggests that the clinical course of IDH-wt astrocytoma, is different from IDH-wt glioblastoma with an early onset and longer survival. As concomitant radiochemotherapy is non-superior in IDH-wt astrocytoma, maximum safe resection is even more important than in classical IDH-wt glioblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.